These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35040990)

  • 1. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
    Ambrosioni J; Rojas Liévano J; Berrocal L; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Ugarte A; Chivite I; Leal L; de Lazzari E; Miró JM; Blanco JL; Martinez E; Mallolas J
    J Antimicrob Chemother; 2022 Mar; 77(4):1133-1139. PubMed ID: 35040990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
    Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
    Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
    Chivite I; Berrocal L; de Lazzari E; Navadeh S; Lluis-Ganella C; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Blanco JL; Martínez E; Mallolas J; Ambrosioni J
    J Antimicrob Chemother; 2024 Aug; 79(8):1775-1783. PubMed ID: 38758191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
    HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
    J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
    Gan L; Xie X; Fu Y; Song Y; Song C; Ren T; Long H
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):211-217. PubMed ID: 38058002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):T171-T175. PubMed ID: 38806363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
    Esser S; Brunetta J; Inciarte A; Levy I; D'Arminio Monforte A; Lambert JS; van Welzen B; Teruya K; Boffito M; Liu CE; Altuntas Aydın O; Thorpe D; Heinzkill M; Marongiu A; Cassidy T; Haubrich R; D'Amato L; Robineau O
    HIV Med; 2024 Apr; 25(4):440-453. PubMed ID: 38148567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
    Ciccullo A; Baldin G; Borghi V; Oreni L; Lagi F; Fusco P; Giacomelli A; Torti C; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
    Int J Antimicrob Agents; 2024 Jan; 63(1):107040. PubMed ID: 37981074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
    Wong A; Brunetta J; De Wet J; Logue K; Loemba H; Saifi T; Mumm D; Marongiu A; Harrison R; Thorpe D; Trottier B
    Medicine (Baltimore); 2024 Apr; 103(16):e37785. PubMed ID: 38640301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):171-175. PubMed ID: 38448360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
    Corona D; Pérez-Valero I; Camacho A; Gutiérrez Liarte Á; Montero-Alonso M; Alemán MR; Ruiz-Seco P; Pérez González A; Riera M; Jarrin I; Rivero-Juárez A; Rivero A
    Int J Antimicrob Agents; 2024 Jan; 63(1):107016. PubMed ID: 37890734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
    Squillace N; Ricci E; Maggi P; Taramasso L; Menzaghi B; De Socio GV; Piconi S; Maurizio Celesia B; Orofino G; Sarchi E; Pellicanò GF; Simeone F; Valsecchi L; Bandera A; Cenderello G; Attala L; Angioni G; Falasca K; Cascio A; Bargiacchi O; Di Biagio A; Bonfanti P;
    PLoS One; 2023; 18(8):e0289132. PubMed ID: 37556481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
    Hidalgo-Tenorio C; Sequera S; Vivancos MJ; Vinuesa D; Collado A; Santos IL; Sorni P; Cabello-Clotet N; Montero M; Font CR; Terron A; Galindo MJ; Martinez O; Ryan P; Omar-Mohamed M; Albendín-Iglesias H; Javier R; Ruz MÁL; Romero A; Garcia-Vallecillos C
    Int J Antimicrob Agents; 2024 Jun; 63(6):107164. PubMed ID: 38574873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
    Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
    Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
    Rocabert A; Borjabad B; Berrocal L; Blanch J; Inciarte A; Chivite I; Gonzalez-Cordon A; Torres B; Ambrosioni J; Martinez-Rebollar M; Laguno M; De La Mora L; Foncillas A; Sempere A; Rodriguez A; Solbes E; Llobet R; Miro JM; Mallolas J; Blanco JL; De Lazzari E; Martinez E
    J Antimicrob Chemother; 2023 Dec; 78(12):2961-2967. PubMed ID: 37875023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.
    Lazzaro A; Bianchini D; Gentilini Cacciola E; Mezzaroma I; Falciano M; Andreoni C; Fimiani C; Santinelli L; Maddaloni L; Bugani G; Ceccarelli G; Mastroianni CM; d'Ettorre G
    Viruses; 2023 May; 15(6):. PubMed ID: 37376522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
    J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.